Interrupted 131I Procedures for Patients With Differentiated Thyroid Cancer: Comparing Thyroxine Withdrawal With Recombinant Thyrotropin Preparation Techniques

Clin Nucl Med. 2017 Apr;42(4):247-249. doi: 10.1097/RLU.0000000000001553.

Abstract

Objective: In patients with differentiated thyroid carcinoma scheduled to receive doses of I for diagnostic or therapeutic purposes, we compared patients prepared with thyroid hormone withdrawal (THW) versus recombinant human thyroid stimulating hormone (rh-TSH) to evaluate the incidence of cancelled procedures because of inadequate thyroid stimulation.

Methods: Thyroid cancer patients after thyroidectomy who were scheduled for diagnostic or therapeutic I procedures between January 2012 and June 2015 were retrospectively reviewed. Patients were divided based on preparation modality (THW vs rh-TSH), and the incidence of cancelled procedures was compared.

Results: Charts from 761 patients were reviewed, 292 THW and 569 rh-TSH. A total of 10 patients (3.4%) in the THW group had cancelled procedures because of insufficient thyroid stimulation (TSH < 20 mU/L). If a TSH threshold of 30 mU/L were used, 57 patients (17.1%) would have been cancelled. Comparing the groups with chi-squared analysis for both TSH thresholds yielded significantly more cancellations in the THW group (P < 0.001).

Conclusions: Our study has shown that THW in preparation for I procedures leads to significantly more cancellations because of insufficient thyroid stimulation as compared with rh-TSH, which led to no cancellations. The added cost and inconvenience to this cancer population should therefore be considered when selecting a preparation modality.

Level of evidence: Retrospective cohort-Level III.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Carcinoma / diagnostic imaging*
  • Carcinoma / drug therapy
  • Carcinoma / radiotherapy
  • Drug Administration Schedule
  • Female
  • Humans
  • Iodine Radioisotopes / therapeutic use*
  • Male
  • Middle Aged
  • Radiopharmaceuticals / therapeutic use*
  • Radiotherapy / methods
  • Thyroid Neoplasms / diagnostic imaging*
  • Thyroid Neoplasms / drug therapy
  • Thyroid Neoplasms / radiotherapy
  • Thyrotropin / administration & dosage*
  • Thyrotropin / adverse effects
  • Thyrotropin / therapeutic use
  • Thyroxine / administration & dosage*
  • Thyroxine / adverse effects
  • Thyroxine / therapeutic use

Substances

  • Iodine Radioisotopes
  • Radiopharmaceuticals
  • Thyrotropin
  • Thyroxine